logo
Plus   Neg
Share
Email

Evotec In Partnership With University Of Oxford

Evotec SE (EVTCY.PK,EVOTF.PK), a German drug discovery and development company, announced a partnership agreement with the University of Oxford regarding access to biospecimens from the biobank Quality in Organ Donation or QUOD. The company did not disclose any financial terms of the agreement.

QUOD is an initiative of The Nuffield Department of Surgical Sciences or NDS at the University of Oxford in close collaboration with the National Health Service Blood and Transplant or NHSBT organisation in the UK.

The QUOD biobank, a joint programme by a consortium of UK academic transplant centres and NHSBT, is funded by NHSBT and the Medical Research Council. It provides blood, urine and tissue samples from heart, lung, liver and kidney from consented organ donors for researchers with anonymised integrated medical records.

Under the terms of the partnership, Evotec will investigate at first samples from 1,000 donors of the QUOD biobank using a comprehensive multi-omics analysis (genomics, transcriptomics, proteomics, metabolomics). This data will complement Evotec's existing patient database, generating a greater understanding of disease mechanisms across indications, i.e. cardio-vascular, kidney, and liver diseases.

Investigation of diseased versus healthy human biomaterial using a multi-omics approach combined with clinical data will provide extensive knowledge, indispensable for advancement of organ transplantation, drug discovery as well as clinical and biomarker research.

QUOD biobank's samples have been collected over several years with QUOD's primary goal to identify biomarkers, explain mechanisms of injury and repair, and improve organ utilisation and transplantation.

Cord Dohrmann, Chief Scientific Officer of Evotec, said, "We are proud to enter this collaboration with the QUOD programme, which expands our strategic partnership with the University of Oxford beyond LAB282, our first-of-its-kind academic BRIDGE partnership. Comprehensive molecular profiling of patient samples will re-define health and disease according to dysregulated molecular disease mechanisms. This will open new doors for intervention and corresponding patient stratification."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Incredible Fish, Inc. has recalled a small quantity of Incredible Stone Crab Mustard Sauce citing undeclared milk, fish, and eggs allergens, the U.S. Food and Drug Administration announced. The Miami-based wholesale seafood distributor sold the recalled product to a limited number of consumers between October 15 and October 22, 2020, primarily through the company's website. Facebook said Tuesday that it has helped 4.4 million people register to vote for the upcoming U.S. presidential election on November 3, exceeding the tech giant's goal of helping 4 million voters to register. In June, Facebook said it created a new Voting Information Center to provide users with authoritative information, including how and when to vote. Facebook has launched cloud-streamed games in the Facebook app and on browser, which are playable instantly, with no downloads required. These cloud-streamed games can be played right alongside those playing instant games in HTML5. The access to cloud games on Facebook will roll out in the US, initially across California, Texas and Northeast and Mid-Atlantic states.
Follow RTT